臨床検査60巻4号

2016年04月発行

今月の特集2 感染症診断に使われるバイオマーカー—その臨床的意義とは？

プロアドレノメデュリン（proADM）

著者： 青木信将¹² 菊地利明²

所属機関： ¹新潟大学医歯学総合病院集中治療部 ²新潟大学医歯学総合研究科呼吸器・感染症内科学分野

ページ範囲：P.422 - P.427

Point

●プロアドレノメデュリン（proADM）は心血管系マーカーであるが，さまざまな特性を有しており，感染症マーカーとしても期待されている．

●感染症診断や原因微生物診断には適さない．

●肺炎などで優れた予後予測能を示す．

参考文献

1）Eto T：A review of the biological properties and clinical implications of adrenomedullin and proadrenomedullin N-terminal 20 peptide (PAMP), hypotensive and vasodilating peptides. Peptides　22：1693-1711，2001

2）Marutsuka K, Nawa Y, Asada Y, et al：Adrenomedullin and proadrenomudullin N-terminal 20 peptide (PAMP) are present in human colonic epithelia and exert an antimicrobial effect. Exp Physiol　86：543-545，2001

3）Bełtowski J, Jamroz A：Adrenomedullin--what do we know 10 years since its discovery? Pol J Pharmacol　56：5-27，2004

4）Bello S, Lasierra AB, Mincholé E, et al：Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology. Eur Respir J　39：1144-1155，2012

5）de Kruif MD, Lemaire LC, Giebelen IA, et al：The influence of corticosteroids on the release of novel biomarkers in human endotoxemia. Intensive Care Med　34：518-522，2008

6）Cavallazzi R, El-Kersh K, Abu-Atherah E, et al：Midregional proadrenomedullin for prognosis in community-acquired pneumonia: a systematic review. Respir Med　108：1569-1580，2014

7）Suberviola B, Castellanos-Ortega A, Llorca J, et al：Prognostic value of proadrenomedullin in severe sepsis and septic shock patients with community-acquired pneumonia. Swiss Med Wkly　142：w13542，2012

8）Krüger S, Ewig S, Giersdorf S, et al：Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ. Am J Respir Crit Care Med　182：1426-1434，2010

9）Schuetz P, Litke A, Albrich WC, et al：Blood biomarkers for personalized treatment and patient management decisions in community-acquired pneumonia. Curr Opin Infect Dis　26：159-167，2013

10）Christ-Crain M, Morgenthaler NG, Stolz D, et al：Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]. Crit Care　10：R96，2006

11）Huang DT, Angus DC, Kellum JA, et al：Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia. Chest　136：823-831，2009

12）Albrich WC, Dusemund F, Rüegger K, et al：Enhancement of CURB65 score with proadrenomedullin (CURB65-A) for outcome prediction in lower respiratory tract infections: derivation of a clinical algorithm. BMC Infect Dis　11：112，2011

13）Renaud B, Schuetz P, Claessens YE, et al：Proadrenomedullin improves Risk of Early Admission to ICU score for predicting early severe community-acquired pneumonia. Chest　142：1447-1454，2012

14）Courtais C, Kuster N, Dupuy AM, et al：Proadrenomedullin, a useful tool for risk stratification in high Pneumonia Severity Index score community acquired pneumonia. Am J Emerg Med　31：215-221，2013

15）Gordo-Remartínez S, Calderón-Moreno M, Fernández-Herranz J, et al: Usefulness of midregional proadrenomedullin to predict poor outcome in patients with community acquired pneumonia. PLoS One　10：e0125212，2015

16）Christ-Crain M, Morgenthaler NG, Struck J, et al：Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study. Crit Care　9：R816-R824，2005

17）Guignant C, Voirin N, Venet F, et al：Assessment of pro-vasopressin and pro-adrenomedullin as predictors of 28-day mortality in septic shock patients. Intensive Care Med　35：1859-1867，2009

18）Suberviola B, Castellanos-Ortega A, Ruiz Ruiz A, et al：Hospital mortality prognostication in sepsis using the new biomarkers suPAR and proADM in a single determination on ICU admission. Intensive Care Med　39：1945-1952，2013

19）Akpinar S, Rollas K, Alagöz A, et al：Performance evaluation of MR-proadrenomedullin and other scoring systems in severe sepsis with pneumonia. J Thorac Dis　6：921-929，2014

20）Andaluz-Ojeda D, Cicuéndez R, Calvo D, et al：Sustained value of proadrenomedullin as mortality predictor in severe sepsis. J Infect　71：136-139，2015